Home
Issues
Aim & Scope
Open Access
Indexing
Why publish with us
Contact
Editorial Board
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Authorship & COI
Principles of Transparency Checklist
Publication Ethics and Publication Malpractice Statement
CrossMark
Data Policies
ORIGINAL STUDY
The health related quality of life of Greek patients with chronic obstructive pulmonary disease
1
9th Department of Pulmonary Medicine, National and Kapodistrian University of Athens, Athens Chest Hospital “Sotiria”, Athens, Greece
2
3rd Department of Pulmonary Medicine, National
and Kapodistrian University of Athens, Athens
Chest Hospital “Sotiria”, Athens, Greece
3
1st Department of Pulmonary Medicine, National and Kapodistrian University of Athens, Athens Chest Hospital “Sotiria”, Athens, Greece
Corresponding author
Charalampos Dimitropoulos
9th Department of Pulmonary Medicine, Athens Chest Hospital “Sotiria”, 152 Mesogion Ave., 11527 Athens, Greece
9th Department of Pulmonary Medicine, Athens Chest Hospital “Sotiria”, 152 Mesogion Ave., 11527 Athens, Greece
Pneumon 2013;26(2):139-151
KEYWORDS
ABSTRACT
Background:
Chronic Obstructive Pulmonary Disease (COPD) is an advancing disease, characterized by progressive deterioration of lung function. The impact of the disease on human health is massive and it affects the health related quality of life (HRQoL) of patients in every aspect. This study assessed HRQoL of Greek patients with COPD and its association with demographic and clinical factors, and compared the findings with with those of COPD studies in other countries. In addition, the cost of pharmaceutical treatment of these patients was assessed.
Material and Methods:
The study group consisted of 136 Greek patients with COPD (103 men, mean age 64.7±9.2 years, mean FEV1 59±25.6% predicted).I Information was recorded about their demographic and clinical parameters. Their HRQoL was assessed using the Greek versions of the Medical Outcomes Study Short Form 12 (SF-12) and St George’s Respiratory Questionnaire (SGRQ).
Results:
The HRQoL of Greek patients with COPD was found to be significantly lower than both that in the general population and that of patients COPD reported in other countries. Almost all the HRQoL scores were shown to be associated with gender, educational and financial status, duration of symptoms, age at onset of symptoms, pack-years of cigarettes smoked, disease stage, degree of dyspnoea, pO2 and pCO2 levels, numbers of medical visits and hospital admissions, participation in rehabilitation programmes, and co-morbidities, such as cardiovascular disease and diabetes mellitus (DM). The average cost of pharmaceutical treatment was assessed at 110 ± 63 € / month and was associated with the stage of the disease, the smoking habit, the degree of dyspnoea, annual numbers of medical visits and admissions and nebulizer usage.
Conclusions:
The HRQoL of Greek patients with COPD is influenced by multiple parameters, which should all be taken into consideration when their treatment is being planned. Cost-effective studies should be made on populations of Greek patients with COPD and more emphasis should be placed on rehabilitation programmes in Greece.
Chronic Obstructive Pulmonary Disease (COPD) is an advancing disease, characterized by progressive deterioration of lung function. The impact of the disease on human health is massive and it affects the health related quality of life (HRQoL) of patients in every aspect. This study assessed HRQoL of Greek patients with COPD and its association with demographic and clinical factors, and compared the findings with with those of COPD studies in other countries. In addition, the cost of pharmaceutical treatment of these patients was assessed.
Material and Methods:
The study group consisted of 136 Greek patients with COPD (103 men, mean age 64.7±9.2 years, mean FEV1 59±25.6% predicted).I Information was recorded about their demographic and clinical parameters. Their HRQoL was assessed using the Greek versions of the Medical Outcomes Study Short Form 12 (SF-12) and St George’s Respiratory Questionnaire (SGRQ).
Results:
The HRQoL of Greek patients with COPD was found to be significantly lower than both that in the general population and that of patients COPD reported in other countries. Almost all the HRQoL scores were shown to be associated with gender, educational and financial status, duration of symptoms, age at onset of symptoms, pack-years of cigarettes smoked, disease stage, degree of dyspnoea, pO2 and pCO2 levels, numbers of medical visits and hospital admissions, participation in rehabilitation programmes, and co-morbidities, such as cardiovascular disease and diabetes mellitus (DM). The average cost of pharmaceutical treatment was assessed at 110 ± 63 € / month and was associated with the stage of the disease, the smoking habit, the degree of dyspnoea, annual numbers of medical visits and admissions and nebulizer usage.
Conclusions:
The HRQoL of Greek patients with COPD is influenced by multiple parameters, which should all be taken into consideration when their treatment is being planned. Cost-effective studies should be made on populations of Greek patients with COPD and more emphasis should be placed on rehabilitation programmes in Greece.
REFERENCES (37)
1.
Murray CJL, Lopez AD. The global burden of disease. A comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. GBD Series Vol 1. Harvard University Press on behalf of the World Health Organization and the World Bank, Cambridge, Massachusetts, 1996.
2.
Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI and WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respiratory Care 2001, 46:798-825.
3.
Tzanakis N, Anagnostopoulou U, Filaditaki V, Christaki P, Siafakas N; COPD group of the Hellenic Thoracic Society. Prevalence of COPD in Greece. Chest 2004; 125:892-900.
4.
European Respiratory Society. European Lung White Book: Huddersfield, European Respiratory Society Journals, Ltd; 2003.
5.
Geitona M, Hatzikou M, Steiropoulos P, Alexopoulos E, Bouros D. The cost of COPD exacerbations: A university hospital – based study in Greece. Respir Med J 2011; 105:402-409.
6.
Maniadakis N, Tzanakis N, Fragoulakis V, Hatzikou M, Siafakas N. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece. Curr Med Res Opin 2006; 22(8):1599-1607.
7.
Jones PW. Quality of life measurement for patients with diseases of the airways. Thorax 1991, 46:676-682.
8.
Curtis JR, Martin DP, Martin TR. Patient-assessed health outcomes in chronic lung disease: what are they, how do they help us, and where do we go from here? Am J Respir Crit Care Med 1997;156:1032– 9.
9.
Kontodimopoulos N, Pappa E, Niakas D, Tountas Y. Validity of SF-12 scores in a Greek general population. Health and Quality of Life Outcomes 2007; 5:55.
10.
Jones PW, Quirk FH, Baveystock CM. The St George’s Respiratory Questionnaire. Respiratory Medicine 1991, 85:25-31.
11.
National Organization for Medicines. Human drugs [internet] [updated 05/07/2011]. Available at: http://www.eof.gr.
12.
Wilson RC, Jones PW. Long-term reproducibility of Borg scale estimates of breathlessness during exercise. Clin Sci (Colch) 1991;80:309–12.
13.
Jones PW, Quirk F, Baveystock C, Littlejohns P. A Self-complete Measure of Health Status for Chronic Airflow Limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis 1992; 145:1321-1327.
14.
Tzanakis N, Samiou M, Lambrini I, Antoniou K, Siafakas N, Bouros D. Evaluation of health-related quality-of-life and dyspnoea scales in patients with idiopathic pulmonary fibrosis. Correlations with pulmonary function tests. Eur J Int Med 2005; 16:105-112.
15.
Ware JE, Kosinski M, Keller SD. How to score the SF-12 physical and mental health summary scales. 2nd edition. Boston, MA: The Health Institute; 1995.
16.
Yfantopoulos J, Saris M. Health related quality of life. Measurement methodology. Archives of Hellenic Medicine 2001; 18(3):218-229.
17.
Azarisman S, Hadzri H, Fauzi R, et al. Compliance to national guidelines on the management of chronic obstructive pulmonary disease in Malaysia: a single centre experience. Singapore Med J 2008; 49(11):886-896.
18.
Antonelli-Incalzi R, Imperiale C, Bellia V, et al; SaRA Investigators. Do GOLD stages of COPD severity really correspond to differences in health status? Eur Respir J 2003; 22:444-449.
19.
Rutten-van Mölken M, Oostenbrink J, Tashkin D, Burkhart D, Monz B. Does Quality of Life of COPD Patients as Measured by the Generic EuroQol Five-Dimension Questionnaire Differentiate Between COPD Severity Stages? Chest 2006; 130:1117-1127.
20.
de Torres J, Casanova C, Hernández C, et al. Gender associated difference in determinants of quality of life in patients with COPD: a case series study. Health and Quality of Life Outcomes 2006; 4:72-80.
21.
Huijsmans R, de Haan A, ten Hacken N, Straver R, van’t Hul A. The clinical utility of the GOLD classification of COPD disease severity in pulmonary rehabilitation. Respir Med 2008; 102:162-171.
22.
Efremidis G, Manolis A, Spiropoulos K. Global Initiative for Chronic Obstructive Pulmonary Disease Statement and HealthRelated Quality of Life. Clin Pulm Med 2005; 12:333-336.
23.
Spencer S, Calverley P, Sherwood Burge S, Jones P; ISOLDE Study Group. Inhaled Steroids in Obstructive Lung Disease. Health Status Deterioration in Patients with Chronic Obstructive Pulmonary Disease. Am J Repir Crit Care Med 2001; 164:122-128.
24.
Diez J, Garrido P, Carballo M, et al. Determinants and predictors of the cost of COPD in primary care: A Spanish perspective. International Journal of COPD 2008; 3(4):701-712.
25.
Man W, Polkey M, Donaldson N, Gray B, Moxham J. Community pulmonary rehabilitation after hospitalization for acute exacerbation of chronic pulmonary disease: randomized controlled study. BMJ 2004; 329:1209-1215.
26.
Ståhl E, Lindberg A, Jansson S-A, et al. Health-related quality of life to COPD disease severity. Health and Quality of Life Outcomes 2005; 3:56-63.
27.
Minas M, Hatzoglou C, Karetsi E, et al. COPD prevalence and the differences between newly and previous diagnosed COPD patients in a spirometry program. Primary Care Respiratory J 2010; 19(4):363-370.
28.
Okubadejo A, Jones PW, Wadzicha J. Quality of life in patients with chronic obstructive pulmonary disease and severe hypoxemia. Thorax 1996; 51:41-47.
29.
Celli B, Cote C, Marin J, et al. The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease. N Engl J Med 2004; 350:1005-1012.
30.
Katsura H, Yamada K, Kida K. Both generic and disease specific health-related quality of life are deteriorated in patients with underweight COPD. Respir Med 2005; 99:624-630.
31.
Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004; 59:387-395.
32.
Sahahin B. Outpatient pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. Chest 2007 – Poster Presentation: 534.
33.
Berry M, Rejeski J, Adair N, Zaccaro D. Exercise Rehabilitation and Chronic Obstructive Pulmonary Disease Stage. Am J Respir Crit Care Med 1999; 160:1248-1253.
34.
Güell R, Casan P, Belda J, et al. Long-term Effects of Outpatient Rehabilitation of COPD: A Randomized Trial. Chest 2000; 117:976-983.
35.
Garuti G, Cilione C, Dell’Orso D, et al. Impact of comprehensive pulmonary rehabilitation on anxiety and depression in hospitalised COPD patients. Monaldi Arch Chest Dis 2003; 59(1):56-61.
36.
Karakatsani A, Andreadaki S, Katsouyanni K, et al. Air pollution in relation to manifestations of chronic pulmonary disease: A nested case – control study in Athens, Greece. European J of Epidemiology 2003; 18(1):45-53.
37.
Ferrer M, Villasante C, Alonso J, et al. Interpretation of quality of life scores from the St George’s Respiratory Questionnaire. Eur Respir J 2002; 19:405-413.
| eISSN: | 1791-4914 |
| ISSN: | 1105-848X |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
